Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their c...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/9/1379 |
| _version_ | 1797520482581348352 |
|---|---|
| author | Vaia Lambadiari John Thymis Dimitris Kouretas Zoi Skaperda Fotios Tekos Foteini Kousathana Aikaterini Kountouri Konstantinos Balampanis John Parissis Ioanna Andreadou Maria Tsoumani Christina Chania Konstantinos Katogiannis George Dimitriadis Aristotelis Bamias Ignatios Ikonomidis |
| author_facet | Vaia Lambadiari John Thymis Dimitris Kouretas Zoi Skaperda Fotios Tekos Foteini Kousathana Aikaterini Kountouri Konstantinos Balampanis John Parissis Ioanna Andreadou Maria Tsoumani Christina Chania Konstantinos Katogiannis George Dimitriadis Aristotelis Bamias Ignatios Ikonomidis |
| author_sort | Vaia Lambadiari |
| collection | DOAJ |
| description | Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (<i>n</i> = 40), liraglutide (<i>n</i> = 40), empagliflozin (<i>n</i> = 40), or their combination (GLP-1RA+SGLT-2i) (<i>n</i> = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (<i>p</i> < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (<i>p</i> < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (<i>p</i> < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (<i>p</i> < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (<i>p</i> < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (<i>p</i> < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier. |
| first_indexed | 2024-03-10T07:57:22Z |
| format | Article |
| id | doaj.art-b0a16e10f84b4eafa9354028f4498c71 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T07:57:22Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-b0a16e10f84b4eafa9354028f4498c712023-11-22T11:47:52ZengMDPI AGAntioxidants2076-39212021-08-01109137910.3390/antiox10091379Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 DiabetesVaia Lambadiari0John Thymis1Dimitris Kouretas2Zoi Skaperda3Fotios Tekos4Foteini Kousathana5Aikaterini Kountouri6Konstantinos Balampanis7John Parissis8Ioanna Andreadou9Maria Tsoumani10Christina Chania11Konstantinos Katogiannis12George Dimitriadis13Aristotelis Bamias14Ignatios Ikonomidis152nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Cardiology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, GreeceDepartment of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, GreeceDepartment of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, GreeceDepartment of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece2nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Cardiology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, GreeceLaboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, GreeceLaboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, GreeceLaboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece2nd Department of Cardiology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Internal Medicine, Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece2nd Department of Cardiology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, GreeceImbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (<i>n</i> = 40), liraglutide (<i>n</i> = 40), empagliflozin (<i>n</i> = 40), or their combination (GLP-1RA+SGLT-2i) (<i>n</i> = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (<i>p</i> < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (<i>p</i> < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (<i>p</i> < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (<i>p</i> < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (<i>p</i> < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (<i>p</i> < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier.https://www.mdpi.com/2076-3921/10/9/1379glucagon-like peptide-1 receptor agonistssodium-glucose cotransporter-2 inhibitorsMalondialdehydeThiobarbituric Acid Reactive Substances2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical |
| spellingShingle | Vaia Lambadiari John Thymis Dimitris Kouretas Zoi Skaperda Fotios Tekos Foteini Kousathana Aikaterini Kountouri Konstantinos Balampanis John Parissis Ioanna Andreadou Maria Tsoumani Christina Chania Konstantinos Katogiannis George Dimitriadis Aristotelis Bamias Ignatios Ikonomidis Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes Antioxidants glucagon-like peptide-1 receptor agonists sodium-glucose cotransporter-2 inhibitors Malondialdehyde Thiobarbituric Acid Reactive Substances 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical |
| title | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
| title_full | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
| title_fullStr | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
| title_full_unstemmed | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
| title_short | Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes |
| title_sort | effects of a 12 month treatment with glucagon like peptide 1 receptor agonists sodium glucose cotransporter 2 inhibitors and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes |
| topic | glucagon-like peptide-1 receptor agonists sodium-glucose cotransporter-2 inhibitors Malondialdehyde Thiobarbituric Acid Reactive Substances 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical |
| url | https://www.mdpi.com/2076-3921/10/9/1379 |
| work_keys_str_mv | AT vaialambadiari effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT johnthymis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT dimitriskouretas effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT zoiskaperda effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT fotiostekos effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT foteinikousathana effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT aikaterinikountouri effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT konstantinosbalampanis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT johnparissis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT ioannaandreadou effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT mariatsoumani effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT christinachania effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT konstantinoskatogiannis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT georgedimitriadis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT aristotelisbamias effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes AT ignatiosikonomidis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes |